Our Clinicians

Setsuko K. Chambers, MD

Director, Division of Women’s Cancers, Arizona Cancer Center
Gynecologic Oncology Surgery & Chemotherapy
Breast and Gynecologic Cancer Research
Professor, Gynecologic Oncology

EDUCATION

Medical School: Brown University Medical School, Providence, RI
Residency: OB/GYN, Yale-New Haven Hospital, New Haven, CT
Fellowship: Gynecologic Oncology, Yale University School of Medicine, New Haven, CT

PROFESSIONAL EXPERIENCE

Yale University School of Medicine, New Haven, CT
Assistant Professor, Gynecologic Oncology, 1986-1990
Associate Professor, Gynecologic Oncology, 1990-1999
Professor, Gynecologic Oncology, 2000-2004
Director of Gynecologic Oncology Fellowship Research, 1994-2000
Director, Gynecologic Oncology Fellowship Program, 2000-2004

Bridgeport Hospital, Bridgeport, CT
Section Chief, Gynecologic Oncology, 1999-2004

The University of Arizona, Tucson, AZ
Professor, Gynecologic Oncology, 2004-present
Director of Women’s Cancers, Arizona Cancer Center, 2004-present
Associate Head for Academic Affairs, Department of OB/GYN, 2004-present

SELECTED PUBLICATIONS

Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. Overexpression of epithelial CSF-1 and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer; contrasted to a protective effect of stromal CSF-1. Clin Cancer Res. 1997;3:999-1007.

Chambers SK, Chambers JT, Schwartz PE, Kohorn EI, Lorber MI, Handschumacher RE, Pizzorno G. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine A in refractory gynecologic cancer patients. J Clin Oncol. 1997;15:1945-1952.

Chambers SK, Ivins CM, Kacinski BM, Hochberg RB. An unexpected effect of glucocorticoids on stimulation of c-fms proto-oncogene expression in choriocarcinoma cells expressing little glucocorticoid receptor. Am J Obstet Gynecol. 2004;190:974-85.

Tangir J, Bonafe N, Gilmore-Hebert M, Chambers SK. SGK-1, a potential regulator of c-fms related breast cancer aggressiveness. Clin Exp Metastasis. 2004;21:477-483.

Toy EP, Bonafe N, Savlu A, Zeiss C, Zheng W, Flick M, Chambers SK. Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis. Clin Exp Metastasis. 2005;22(1).

Bonafe N, Gilmore-Hebert M, Folk NL, Azoudi M, Zhou Y, Chambers SK. Gyceraldehyde-3-Phosphate dehydrogenase binds to the AU-rich 3’ untranslated region of colony-stimulating factor-1 messenger RNA in human ovarian cancer cells: possible role in colony-stimulating factor-1 posttranscriptional regulation and tumor phenotype. Cancer Res. 2005 May 1;65(9):3762-3771.

For more information:

Division of Women's Cancers
Arizona Cancer Center
1515 N. Campbell Ave.
PO Box 245024
Tucson, AZ 85724-5024
Phone: 520-626-0950
Fax: 520-626-8574
E-mail: sskszek@azcc.arizona.edu

	Our Clinicians Setsuko K. Chambers, MD Director, Division of Women’s Cancers, Arizona Cancer Center Gynecologic Oncology Surgery & Chemotherapy Breast and Gynecologic Cancer Research Professor, Gynecologic Oncology EDUCATION Medical School: Brown University Medical School, Providence, RI Residency: OB/GYN, Yale-New Haven Hospital, New Haven, CT Fellowship: Gynecologic Oncology, Yale University School of Medicine, New Haven, CT PROFESSIONAL EXPERIENCE Yale University School of Medicine, New Haven, CT Assistant Professor, Gynecologic Oncology, 1986-1990 Associate Professor, Gynecologic Oncology, 1990-1999 Professor, Gynecologic Oncology, 2000-2004 Director of Gynecologic Oncology Fellowship Research, 1994-2000 Director, Gynecologic Oncology Fellowship Program, 2000-2004 Bridgeport Hospital, Bridgeport, CT Section Chief, Gynecologic Oncology, 1999-2004 The University of Arizona, Tucson, AZ Professor, Gynecologic Oncology, 2004-present Director of Women’s Cancers, Arizona Cancer Center, 2004-present Associate Head for Academic Affairs, Department of OB/GYN, 2004-present SELECTED PUBLICATIONS Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. Overexpression of epithelial CSF-1 and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer; contrasted to a protective effect of stromal CSF-1. Clin Cancer Res. 1997;3:999-1007. Chambers SK, Chambers JT, Schwartz PE, Kohorn EI, Lorber MI, Handschumacher RE, Pizzorno G. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine A in refractory gynecologic cancer patients. J Clin Oncol. 1997;15:1945-1952. Chambers SK, Ivins CM, Kacinski BM, Hochberg RB. An unexpected effect of glucocorticoids on stimulation of c-fms proto-oncogene expression in choriocarcinoma cells expressing little glucocorticoid receptor. Am J Obstet Gynecol. 2004;190:974-85. Tangir J, Bonafe N, Gilmore-Hebert M, Chambers SK. SGK-1, a potential regulator of c-fms related breast cancer aggressiveness. Clin Exp Metastasis. 2004;21:477-483. Toy EP, Bonafe N, Savlu A, Zeiss C, Zheng W, Flick M, Chambers SK. Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis. Clin Exp Metastasis. 2005;22(1). Bonafe N, Gilmore-Hebert M, Folk NL, Azoudi M, Zhou Y, Chambers SK. Gyceraldehyde-3-Phosphate dehydrogenase binds to the AU-rich 3’ untranslated region of colony-stimulating factor-1 messenger RNA in human ovarian cancer cells: possible role in colony-stimulating factor-1 posttranscriptional regulation and tumor phenotype. Cancer Res. 2005 May 1;65(9):3762-3771. For more information:
Home Appointments Our Clinicians Research Cancer by Site Links
Division of Women's Cancers Arizona Cancer Center 1515 N. Campbell Ave. PO Box 245024 Tucson, AZ 85724-5024 Phone: 520-626-0950 Fax: 520-626-8574 E-mail: sskszek@azcc.arizona.edu
	All contents ©2005 Arizona Board of Regents. All rights reserved. The University of Arizona is an EEO/AA - M/W/D/V Employer.